Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. Managing total funds of approx. €500 million, Sunstone Life Science Ventures is one of the largest Nordic venture capital investors.
Founded in July 2009, Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions. Innovative projects from Academia and research institutions, aspiring to meet unmet medical need is an important pillar of the firm‘s investment strategy, a second is venture capital financings of innovative young companies in Biotech and MedTech; all with a strong focus on innovative drug development approaches.
BERNINA BioInvest Ltd is an investment fund focused on early stage biotech/ medtech investment primarily in Switzerland.
Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over €350M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.6 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.
Founded in 1997, Schroder Adveq is a leading private equity investment manager in specialist strategies with $11.5 billion of assets under management as at 31 March 2020. Since 2017, it has been a wholly owned subsidiary of Schroders plc. It offers both funds and tailored solutions which enable its clients to access select global private market segments through primary, secondary and direct/co-investments. Schroder Adveq’s client base comprises institutional investors such as pension funds and insurance companies, as well as private clients, located in Europe, North America, and the Asia-Pacific region. Many of them are repeat, long-term clients with whom the firm has developed a role as a trusted partner.
Essential Investments is a seed capital fund focusing on high tech companies within the life sciences sector. The Netherlands-based fund provides seed and early stage investments for R&D-intensive startups and ventures. Backed by experienced angel investors and a strong network, the fund uses a hands-on mentality to help innovations reach the market.
The Lichtsteiner Foundation invests in early stage start-ups (in Medtech, Life Science, Mental Health, Public Health and Wellbeing), to help pioneers bring their inventions to life.
The Foundation focuses on impact investing by providing funding in the form of equity.